Dissertations / Theses on the topic 'Hereditary motor neuropathy, HMN'

Abstract Neurodegenerative disorders are a diverse group of disorders that affect specific subsets of neurons. Motor neuron diseases, neurodegenerative disorders of motor neurons, are seen commonly as sporadic cases and less frequently as familial disease forms. The familial forms show genetic and phenotypic heterogeneity. Clinically motor neuron diseases may be seen as rapidly progressive disorders like amyotrophic lateral sclerosis, ALS or slowly progressive disorders like hereditary motor neuropathies, HMN. The only proven causes for motor neuron diseases are gene mutations that lead to motor neuron degeneration in familial disease forms. Only some of these genes have been identified and have contributed greatly to our understanding of the neurobiology of familial and sporadic disease forms. Identification of additional disease causing genes would help enhance our knowledge of the pathophysiological mechanisms underlying all forms of motor neuron disorders, which would lead to early diagnoses, effective prophylaxis and efficient therapies for these disorders. This study aimed to find gene mutations that cause rapid and slowly progressive familial motor neuron disorders in Australian families and to determine their relevance to sporadic forms of motor neuron disease. The familial forms of ALS show reduced disease penetrance, that is, not all gene mutation carriers manifest the disease. This study examines ALS penetrance in a group of Australian families. The most frequently observed mutations in ALS families are cytosolic superoxide dismutase/SOD1 gene mutations. In a collection of ALS families in our centre, families without the common SOD1 gene mutations were genotyped for other ALS genes and loci and studied using genetic linkage and haplotype analyses. Studies in a large Australian ALS family further confirmed genetic heterogeneity in non-SOD familial ALS, all known autosomal dominant ALS genes and chromosomal loci were excluded as cause of disease in this family. Such families can be studied further to identify additional disease genes and loci mapped in other ALS families. These families represent powerful resources for identification of additional ALS genes. Identifying the pathogenic genes in families with reduced disease penetrance may be more relevant to sporadic forms of disease. dHMN is a chronic neurodegenerative disorder predominantly affecting motor neurons. In a large Australian dHMN family, all the known dHMN genes and chromosomal loci were excluded as cause of disease. A genome wide microsatellite screen was performed in this family and genetic linkage was established to a novel 12.98 Mb locus on chromosome 7q34.2-q36. Candidate genes in this large interval will be screened based on their function and expression profile. Identification of a new dHMN locus provides the basis for future identification of a novel gene involved in motor neuron degeneration. Genes in dHMN have been shown to be pathogenic in ALS and Charcot Marie Tooth syndromes. The new locus for dHMN mapped in this project would lead to identification of a novel dHMN gene, which may elucidate the pathogenesis underlying a wide range of neurodegenerative disorders.

Doctor of Philosophy
Abstract Neurodegenerative disorders are a diverse group of disorders that affect specific subsets of neurons. Motor neuron diseases, neurodegenerative disorders of motor neurons, are seen commonly as sporadic cases and less frequently as familial disease forms. The familial forms show genetic and phenotypic heterogeneity. Clinically motor neuron diseases may be seen as rapidly progressive disorders like amyotrophic lateral sclerosis, ALS or slowly progressive disorders like hereditary motor neuropathies, HMN. The only proven causes for motor neuron diseases are gene mutations that lead to motor neuron degeneration in familial disease forms. Only some of these genes have been identified and have contributed greatly to our understanding of the neurobiology of familial and sporadic disease forms. Identification of additional disease causing genes would help enhance our knowledge of the pathophysiological mechanisms underlying all forms of motor neuron disorders, which would lead to early diagnoses, effective prophylaxis and efficient therapies for these disorders. This study aimed to find gene mutations that cause rapid and slowly progressive familial motor neuron disorders in Australian families and to determine their relevance to sporadic forms of motor neuron disease. The familial forms of ALS show reduced disease penetrance, that is, not all gene mutation carriers manifest the disease. This study examines ALS penetrance in a group of Australian families. The most frequently observed mutations in ALS families are cytosolic superoxide dismutase/SOD1 gene mutations. In a collection of ALS families in our centre, families without the common SOD1 gene mutations were genotyped for other ALS genes and loci and studied using genetic linkage and haplotype analyses. Studies in a large Australian ALS family further confirmed genetic heterogeneity in non-SOD familial ALS, all known autosomal dominant ALS genes and chromosomal loci were excluded as cause of disease in this family. Such families can be studied further to identify additional disease genes and loci mapped in other ALS families. These families represent powerful resources for identification of additional ALS genes. Identifying the pathogenic genes in families with reduced disease penetrance may be more relevant to sporadic forms of disease. dHMN is a chronic neurodegenerative disorder predominantly affecting motor neurons. In a large Australian dHMN family, all the known dHMN genes and chromosomal loci were excluded as cause of disease. A genome wide microsatellite screen was performed in this family and genetic linkage was established to a novel 12.98 Mb locus on chromosome 7q34.2-q36. Candidate genes in this large interval will be screened based on their function and expression profile. Identification of a new dHMN locus provides the basis for future identification of a novel gene involved in motor neuron degeneration. Genes in dHMN have been shown to be pathogenic in ALS and Charcot Marie Tooth syndromes. The new locus for dHMN mapped in this project would lead to identification of a novel dHMN gene, which may elucidate the pathogenesis underlying a wide range of neurodegenerative disorders.

The distal hereditary motor neuropathies (dHMN) are a clinically and genetically heterogeneous group of disorders that primarily affect motor neurons, without significant sensory involvement. Using genome wide linkage analysis in a large Australian family (CMT54), a form of dHMN was previously mapped by this laboratory, to a 12.98 Mb interval on chromosome 7q34-q36. The axonal neuropathy seen in this family was classified as dHMN1; with autosomal dominant inheritance, early but variable age of onset, and muscle weakness and wasting affecting the lower limbs. In this project, genetic linkage analysis of the chromosome 7q34-q36 disease interval was carried out in the original family (CMT54) and 20 smaller families from an Australian dHMN cohort. Fine mapping in family CMT54, including unaffected individuals suggested a minimum probable candidate interval of 6.92 Mb, flanked by markers D7S615 and D7S2546 within the 12.98 Mb critical disease interval. Of the additional dHMN families, one (family CMT44) achieved suggestive linkage to the chromosome 7q34-q36 disease locus with a LOD score of 2.02. Mutation screening was carried out in family CMT54 at the chromosome 7q34-q36 locus. The 12.9 Mb disease interval contains 89 annotated protein-coding genes, of which 60 lay within the prioritised 6.92 Mb interval. A combination of methods was used to screen these genes for a putative pathogenic mutation. Functional candidate genes were identified via a literature and database search. The coding exons of 35 prioritised candidate genes were sequenced and no pathogenic mutation was identified. Cytogenetic analysis excluded large scale chromosomal abnormalities. Array based comparative genomic hybridisation of the 7q34-q36 interval in patients did not identify any pathogenic duplications or deletions. Next generation sequencing (NGS) techniques were used to identify sequence variants within the remaining genes within the 7q34-q36 interval and elsewhere in the genome. Two NGS based approaches were applied to mutation screening in family CMT54. Initially, the chromosome 7q34-q36 disease interval was analysed in one affected individual using a custom designed DNA capture microarray and 454 GS FLX (Roche) sequencing. Approximately 80% of patient coding exons were captured, sequenced and no pathogenic mutations were identified. The chromosome 7q34-q36 target captured DNA sample was also re-sequenced along with an additional two affected individuals and one unaffected parent using exome capture and Solexa (Illumina) sequencing. Combined, 99.5% of coding exons were sequenced in the chromosome 7q34-q36 interval and all sequence variants that were identified were excluded from a pathogenic role. Sequence variants identified elsewhere in the exome were also excluded from a pathogenic role. Exome sequencing of dHMN family CMT44 did not identify any putative pathogenic mutation at the chromosome 7q34-q36 locus. The exomes of four affected and one unaffected individuals were sequenced. Exome wide analysis identified a potential digenic inheritance in CMT44 of a previously published MFN2 mutation causing a mild CMT2 phenotype and a second mutation causing a dHMN phenotype. Potential candidate mutations for dHMN were identified in two genes, PCDHGA4 and DNAH11. PCDHGA4, was previously shown to function in the brain and spinal cord, and deletion of PCDHG genes in a mouse model causes a severe neurodegenerative phenotype. The gene mutation causing dHMN that maps to chromosome 7q34-q36 remains to be identified. The disease mutation may lie in a coding region not captured by current exome platforms, a non-coding region, or the mutation may cause disease through an alternate mechanism not detected by the methods employed in this thesis. Future studies should concentrate on transcriptome analysis by next-gen RNA sequencing, which may identify unknown transcripts and exons that map to chromosome 7q34-q36 or highlight sequence variants located in regulatory elements. Identification of new gene mutations is critical to further understanding the biochemical and cellular processes underlying dHMN. Although the causative mutation for dHMN on 7q34-q36 was not identified, a significant proportion of the disease interval has been excluded using a combination of traditional and new technologies. The purpose of this thesis is to identify new gene mutations causing dHMN. The genetic and functional data presented here suggest this will be a difficult task; the genetic heterogeneity complicates genetic analysis and the multiple molecular mechanisms implicated to date make it difficult to pinpoint specific candidate genes. The identification of additional genes and genetic modifiers is necessary to increase our understanding of the disease mechanisms causing dHMN and related neuropathies. This will directly aid in the diagnosis and classification of these neurodegenerative diseases and may lead to new therapeutics and treatment strategies.

Congenital Hypomyelination (CH) is the most severe demyelinating form of Hereditary Motor and Sensory Neuropathies and manifests at birth in human. Some subtypes of CH are due to dommant mutations in the gene coding for PO glycoprotein, which fiinctions as a homophilic adhesion protein, responsible for compaction of opposing myelin lamellae. By homologous recombination in ES cells, we have generated a mouse containing a nonsense mutation m the intracellular portion of PO (Q215X) that, in the heterozygous state, is associated with CH neuropathy in humans.

Hereditary Motor and Sensory Neuropathy-Russe (HMSNR) is a rare recessive form of Charcot-Marie-Tooth disease (CMT) that has been identified in the European Gypsy (Roma) population. Clinically, HMSNR manifests with typical CMT symptoms, while no associated features have been detected. Distinct neuropathological features of HMSNR include the presence of numerous clusters of thinly myelinated fibres originating from regenerative activity. HMSNR has been previously mapped to chromosome 10q using a large Bulgarian Gypsy kindred. Subsequent identification of related chromosome 10q haplotypes in Spanish and Romanian Gypsy families suggested a founder mutation in the Gypsy population as the cause of HMSNR. This thesis describes the refined mapping of the HMSNR gene by generating a high-density physical-genetic map of the HMSNR region containing 20 microsatellite markers and 229 SNPs and insertion/deletions which allowed meticulous mapping of recombination breakpoints resulting in a reduction of the HMSNR gene region from 1 Mb to just 63.8 kb. Analysis of positional candidates by direct sequencing included 14 known genes, 7 predicted genes and 42 expressed sequence tags (ESTs) nonoverlapping with the genes. 78 putative HMSNR mutations were identified, two of which exhibit complete segregation with the HMSNR phenotype. Both are located in the so-called testis-specific part of unexpected candidate gene hexokinase 1 (HK1), in a rare alternative untranslated 5’ exon of HK1 and in the adjacent downstream intron. Expression analysis of transcripts containing the alternative exon suggests that the exon is not confined to testis but may be expressed in the nervous system. It remains to be speculated how a gene that functions in the fundamental process of energy generation might be involved in a neuropathy. Further investigations are likely to expand the knowledge about the importance of HK1 in the peripheral nervous system and may elucidate new roles of HK1

Peripheral neuropathy associated with agenesis of the corpus callosum (ACCPN or HMSN/ACC) is a severe polyneuropathy affecting both the peripheral nervous system and the central nervous system. It is transmitted as an autosomal recessive trait and is particularly frequent in the French Canadian population of Quebec (Canada). The disease was linked to chromosome 15 in 1996 by Dr. Rouleau's team.
We genotyped polymorphic markers in the ACCPN candidate region on chromosome 15 in over 67 patients and 200 control individuals. Observation of affected haplotypes confirmed the presence of a founder effect in the French Canadian population. Recombination analysis reduced the candidate interval to approximately 2 cM between markers D15S1040 and ACTC on chromosome 15. Linkage disequilibrium analysis suggested the gene resides nearest marker D15S1232. A physical map of the newly refined candidate region was constructed using YAC, BAC and PAC clones. These clones were used to confirm the position of candidate ESTs and genes as being either within or outside the ACCPN candidate region.
The connexin 36 gene, which was confirmed to reside within the region, was excluded as the gene responsible for ACCPN using SSCP analysis. The SLC12A6 gene was also confirmed to reside within the candidate interval and was tested for mutations using SSCP, dHPLC and sequence analyses. We found a total of four disease-specific mutations in SLC12A6, all of which are expected to truncate the KCC3 protein (the protein produced by the SLC12A6 gene). Two of the four mutations were identified in the French Canadian population; 80 French Canadian ACCPN patients are homozygous for the c.2436delG in exon 18 and one French Canadian patient is a compound heterozygote, having the c.2436delG mutation as well as the 1584_1585delCTinsG mutation in exon 11. Two additional mutations were identified in one Turkish and one Italian family in exons 22 and 15 respectively. The effects of the c.2436delG mutation on KCC3 function was studied in X. laevis oocytes and the truncated protein is not functional. Finally, collaborators at Vanderbilt University disrupted the slc12a6 gene in the mouse and found a phenotype similar to the human disease.
Identification of SLC12A6 as the gene mutated in ACCPN will allow for accurate molecular diagnosis as well as carrier testing in the French Canadian population. It is also the first step in understanding the molecular mechanism leading to the disease.

Neurodegenerative diseases are becoming increasingly prevalent due to the ageing population, and are among the major contributors to disability and disease worldwide. The identification of the gene defects responsible for many of these conditions has played a major role in our understanding of the pathogenic processes involved, and provided opportunity to develop targeted treatment strategies. Cholinergic neurotransmission supports a wide range of physiological and behavioural processes and its dysfunction of cholinergic signalling has been associated with a number of disorders, including myasthenias, cardiovascular disease(1), attention-deficit hyperactivity disorder (ADHD) (2), Alzheimer’s disease (ADi), schizophrenia, addiction(3), and depression(4). SLC5A7 encodes the Na+/Cl- dependent, high-affinity choline transporter (CHT) which represents the rate limiting step in acetylcholine (Ach) synthesis and is critical for normal cholinergic signalling. The work in this thesis details two new inherited disorders, caused by distinct pathogenic disease mechanisms, associated with novel SLC5A7 mutations. Chapter three documents the discovery of two autosomal-dominantly acting SLC5A7/CHT mutations associated with adult onset motor neurone disorders. Initially we identified a frameshift mutation that results in premature truncation of the transporter protein in a large Welsh kindred affected with distal hereditary motor neuropathy type VII (dHMN-VII), in which neurodegeneration and muscle paresis is largely restricted to the distal limb muscles and vocal cords. The mutation responsible results in the dominant-negative interference of the mutant molecule with function of the wild type choline transporter, resulting in significantly reduced (although not completely abolished) transporter activity. This finding is further evidenced by the discovery of a second dHMN family associated with a distinct frameshift SLC5A7 mutation indicative of a similar dominant-negative disease mechanism. Together these findings corroborate a dominant-negative disease mechanism arising from C-terminal truncating SLC5A7 mutations associated with dHMN, and provide further insight into the role of aberrant choline transporter function in neurological disease. Chapter four describes N-terminal missense mutations located in the transmembrane spanning region of SLC5A7/CHT, associated with a severe infantile neuromuscular disorder characterised by predominantly central hypotonia and developmental delay. The phenotypic effects of these mutations are likely to result from the near abolition of CHT-mediated choline transport in homozygous individuals, and are in keeping with those observed in CHT knock-out mouse models(5). The development of a mouse model of the human motor neurone disease arising from SLC5A7 frameshift mutations should allow for further investigation of the mechanism by which truncated CHT leads to the dHMN phenotype. Chapter 5 details treatment hypotheses for dHMN, as well as the generation of a patient-specific knock-in mouse model carrying an Slc5a7 mutation orthologous to that identified in dHMN-VII families in chapter 3, and results from preliminary neurological phenotyping of the mouse model. This model will be crucially important for the exploration of treatment options in dHMN-VII motor neurone disease as a prelude to clinical trials in humans.

O controle postural na doença de Charcot-Marie-Tooth (CMT) está subsidiado em estudos com adultos, nos quais deformidades distais, desequilíbrios musculares e aspectos maturacionais estão bem documentados. Para infância e adolescência, o controle postural permanece por ser explorado e pode contribuir para elucidar como um sistema neuromuscular imaturo lida com a doença em curso. Neste contexto, foi proposto um estudo de desenho transversal (Estudo 1) composto por crianças e adolescentes com CMT (encaminhados ao Ambulatório CMT-Infantil do Centro de Reabilitação do HCFMRP-USP; Grupo CMT) e seus pares saudáveis (Grupo Controle), e outro longitudinal (Estudo 2), composto exclusivamente de crianças e adolescentes com CMT. O Estudo 1 caracterizou a oscilação postural e explorou sua interação com variáveis musculoesqueléticas, a partir da comparação do Grupo CMT e Grupo Controle, sendo composto por 53 participantes de ambos os sexos, idade entre 6 e 18 anos, sendo 24 saudáveis e 29 com CMT. Foram coletados dados de massa, estatura, base de apoio, Índice Postural do Pé (IPP), amplitudes passivas de movimento, força muscular isométrica de membros inferiores, medidas de desempenho (teste de caminhada dos 6 min -T6, teste dos 10 m - T10, salto horizontal - SH) e de equilíbrio (estabilometria, Escala de Equilíbrio Pediátrica - EEP). A força muscular isométrica dos grupos musculares inversores, eversores, dorsiflexores, flexores plantares, flexores e extensores de joelho e extensores de quadril foi medida bilateralmente com um dinamômetro manual (Lafayette, modelo 01163). Para avaliação estabilométrica foi usada uma plataforma de força (Bertec, modelo FP 4060-08), com frequência de amostragem de 100 Hz, tempo de registro de 30 s por tentativa. As 4 condições de teste (olhos abertos/superfície rígida; olhos abertos/superfície deformável; olhos fechados/superfície rígida; olhos fechados/superfície deformável) foram repetidas aleatoriamente por 3 vezes, intervaladas por 30 s, perfazendo 12 tentativas. Foram extraídas a área da elipse de confiança, velocidade (total, mediolateral e anteroposterior), frequência (total, mediolateral e anteroposterior) e o Quociente de Romberg (QRv) por meio do programa MATLAB (R2014a), usando um filtro digital Butterworth passa-baixa de 4a ordem, com frequência de corte de 7 Hz. O programa SPSS (versão 17) foi usado para análise estatística (nível de significância de 5%). No aspecto musculoesquelético (amplitude de dorsiflexão, ângulo poplíteo e força muscular da maioria dos grupos testados) e nos testes de desempenho (T10, T6 e SH), os resultados mostraram que o grupo CMT exibiu valores inferiores ao Controle (p<0,05). Quanto ao controle postural, comparações intragrupo das condições de teste no grupo CMT evidenciaram incremento na área e velocidades do centro de pressão (CP), mas não nas frequências, conforme a complexidade da tarefa. Nas comparações intergrupos, tanto a EEP quanto a estabilometria evidenciaram menor equilíbrio no grupo CMT quando comparado ao Controle (aumento da área de confiança da elipse e das velocidades, associadas a um decréscimo da frequência do CP) (p<0,05). As interações mais relevantes entre fatores musculoesqueléticos e equilíbrio sugerem melhor controle postural para indivíduos com pés são planos e amplitudes de dorsiflexão reduzidas. O Estudo 2 buscou detectar alterações no controle postural nos participantes que foram seguidos por 6 e 12 meses consecutivos, sendo 22 com CMT de ambos os sexos, idade entre 6 e 18 anos. Registros da oscilação postural, das variáveis musculoesqueléticas e de desempenho foram analisados em intervalos de 6 meses (AV1, AV2 e AV3). Os programas SPSS (versão 17) e R Core Team (2016) foram usados para análise estatística. O teste de Wilcoxon foi usado para comparar variáveis estabilométricas do seguimento semestral e anual e para uma análise complementar, considerando os subgrupos de 6 a 9 anos (n=8) e de 10 a 17 anos (n=9). O comportamento das variáveis musculoesqueléticas foi analisado com o modelo linear de efeitos mistos. O teste t de Student para amostras pareadas foi usado para analisar T10, T6 e SH. O IPP e EEP foram analisados com o teste exato de Fisher. Os resultados mostraram que não houve mudanças significativas na estabilometria entre AV1 e AV2 ou AV1 e AV3. Nas comparações entre AV1 e AV2, houve aumento significativo no ângulo poplíteo, na força dos grupos musculares eversores de tornozelo e extensores de quadril, no SH e a força muscular dos extensores de joelho sofreu decréscimo (p<0,05). Nas comparações entre AV1 e AV3, houve aumento significativo da força muscular dos grupos inversores, eversores, dorsiflexores e extensores de joelho (p<0,05). A análise complementar do seguimento anual identificou reduções significativas na amplitude de dorsiflexão, velocidade mediolateral (condições olhos abertos/superfície rígida e olhos fechados/superfície rígida) e velocidade total (condições olhos abertos/superfície rígida e olhos fechados/superfície rígida) no subgrupo de crianças (n=8) (p<0,05). No subgrupo de adolescentes (n=9), houve aumento significativo da força muscular de inversores, dorsiflexores e extensores de joelho (p<0,05) enquanto a estabilometria permaneceu inalterada. Em suma, os resultados do Estudo 1 e 2 permitem concluir que o controle postural ii deficitário de crianças e adolescentes com CMT é mensurável com base nas variáveis estabilométricas extraídas da análise global; é expresso por grandes e rápidas oscilações do CP, nas quais a frequência não distingue as condições de teste quando comparadas aos seus pares saudáveis. A velocidade do CP parece refletir as mudanças na estabilidade postural quando crianças e adolescentes são analisados como subgrupos distintos. Além disso, seguimentos anuais parecem ser suficientes para detectar mudanças no controle postural, nas variáveis musculoesqueléticas e de desempenho.
Postural control in Charcot-Marie-Tooth disease (CMT) is supported in studies with adults, in which distal deformities, muscular imbalances and maturational aspects are well documented. For childhood and adolescence, standing balance remains to be explored and may contribute to elucidate how an immature neuromuscular system deals with the ongoing disease. In this context, a crosssectional study (Study 1) composed of children and adolescents with CMT (referred to the CMTInfantile Ambulatory of the HCFMRP-USP Rehabilitation Center, CMT Group) and their healthy peers (Control Group), and another longitudinal (Study 2), composed exclusively of children and adolescents with CMT were proposed. Study 1 characterized the postural oscillations and explored its interaction with musculoskeletal variables from the comparison of the CMT Group and Control Group, being composed of 53 participants of both sexes, age between 6 and 18 years, being 24 healthy and 29 with CMT. Mass, height, base of support, foot postural index (PPI), passive amplitudes of movement, isometric muscle strength of lower limbs, performance measures (6-min walk test -T6, 10- T10, horizontal jump - SH) and balance (stabilometry, Pediatric Balance Scale - EEP) were collected. The isometric muscle strength of the inversion, dorsiflexion, plantarflexion, knee extension, knee flexion and hip extension was measured bilaterally with a manual dynamometer (Lafayette, model 01163). Stabilometric evaluationused a force platform (Bertec, model FP 4060-08), with sampling frequency of 100 Hz, recording time of 30 s per trial. The 4 test conditions (open eyes / hard surface, open eyes / deformable surface, closed eyes / hard surface, closed eyes / deformable surface) were randomly repeated 3 times, intervals for 30 s, making 12 trials. The confidence ellipse area, velocity (total, mediolateral and anteroposterior), frequency (total, mediolateral and anteroposterior) and the Romberg Quotient (QRv) were extracted using MATLAB program (R2014a), adopting a 4th order Butterworth digital low-pass filter and a cut-off frequency of 7 Hz. Statistical analysis used the SPSS program (version 17) and it was adopted level of significance of 5%. In the musculoskeletal aspect (amplitude of dorsiflexion, popliteal angle and muscular strength of most of the groups tested) and performance tests (T10, T6 and SH), CMT group showed values lower than Control (p <0.05). For balance, intragroup comparisons of the test conditions in the CMT group evidenced an increased area and velocities of the pressure center (CP), but not the frequencies, according to the complexity of the task. In the intergroup comparisons, EEP and stabilometry showed less postural control in the CMT group when compared to the Control (increased confidence ellipse area and velocities associated with a decrease in CP frequency) (p <0.05). The most relevant interactions between musculoskeletal and oscillations of CP suggest better postural control for subjects the flat feet and reduced dorsiflexion amplitudes. Study 2 comprised 22 participants with CMT of both sexes, aged between 6 and 18 years and it sought to detect changes in postural oscillations in CMT with 6 and 12 consecutive months of follow-up. Postural oscillations, musculoskeletal and performance variables were analyzed at 6-month intervals (AV1, AV2 and AV3). SPSS (version 17) and R Core Team (2016) programs were used for statistical analysis. The Wilcoxon test was used to compare stabilometric variables of the bi-annual and annual follow-up and to a complementary analysis, considering the subgroups of 6 to 9 years (n = 8) and 10 to 17 years (n = 9). The linear mixed effects model analyzed the musculoskeletal variables. Student\'s t-test for paired samples was used to analyze T10, T6 and SH. The Fisher\'s exact test analyzed the IPP and EEP. The results showed no significant changes in the stabilometry between AV1 and AV2 or AV1 and AV3. Comparisons between AV1 and AV2 showed significant increase in the popliteal angle strength of the ankle evertors and hip extensors SH while the muscle strength of knee extensors decreased (p <0.05). Comparisons between AV1 and AV3, showed a significant increase in the muscular strength for inversion, eversion, dorsiflexion and knee extension groups (p <0.05). The complementary analysis of the annual follow-up identified significant reductions in dorsiflexion amplitude, mediolateral velocity (open eyes / rigid surface and closed eyes / rigid surface) and total velocity (open eyes / rigid surface and closed eyes / rigid surfaces) in the subgroup of children (n = 8) (p <0.05). Subgroup of adolescents (n = 9) showed a significant increase in the muscular strength of inverters, dorsiflexors and knee extensors (p <0.05) while the stabilometry remained unchanged. In summary, the results of Study 1 and 2 allow us to conclude that the poor postural control of children and adolescents with CMT is measurable based on the stabilometric variables extracted from the global analysis; is iv expressed by large and rapid CP oscillations, in which frequency does not distinguish the test conditions when compared to their healthy counterparts. The velocity of CP seems to reflect changes in postural stability when children and adolescents are analyzed as distinct subgroups. In addition, annual follow-up appears to be sufficient to detect changes in postural control, musculoskeletal and performance variables.

The Charcot-Marie-Tooth disease (CMT) is peripheral neuropathy genetically inherited most common worldwide. The most cases of CMT can be classified into two major categories of the nature of the primary nerve injury: CMT type 1 and type 2. The main clinical symptoms are muscle weakness and decreased sensation in the legs and feet, changes in gait and balance. The objectives of this study were to conduct a systematic review of the balance and functionality of individuals with the disease of Charcot-Marie-Tooth (CMT), as well as assess the muscle strength, balance and functionality of individuals with the disease of Charcot-Marie-Tooth type 2 ( CMT2). Methods: A comprehensive literature search was performed using as a database MEDLINE, PubMed, Web of Science, Scopus (1980- 2015). Furthermore, an observational and cross-sectional study was conducted through interviews and clinical evaluation of individuals with CMT2 disease in the city Tobias Barreto. The sample consisted of a group of 15 patients with CMT2 (GCMT2) and a control group (CG), with healthy subjects matched for age and gender with CMT2 group. Individuals with CMT were classified by Neuropathic scale of Charcot-Marie-Tooth disease (Neuropathy Scale Charcot-Marie-Tooth - CMTNS) that assesses the degree of severity of the disease. The muscle strength of the lower limbs was evaluated by a hand dynamometer. The balance was measured through footwork stabilometer and Berg Balance Scale. Functional assessment was measured by the Timed Up Go test (TUG). Results: In the systematic review were selected 18 articles, most of the cross-sectional and performed in Europe. The types of study were prevailed on assessment of balance and functionality, rehabilitation treatment and natural evolution of CMT disease. The number of participants per study ranged 6-211 affected individuals. In the second article, there was a statistically significant difference between the GCMT2 and GC for muscle strength of all assessed muscles (ankle extensor: p = <0.0001, plantarflexors: p = <0.0001, inverters: p = <0.0001, eversors: p = 0.0016).For the VCoPAP and DCopAP parameters stabilometry for open and closed eyes, respectively (p = 0.0123, p = 0.0183, p = 0.0132, p = 0.0129) for the Berg balance scale (p = 0.0066) and the TUG (p = 0.0003) test. The most evident correlations were between all variables and CMTNS. In addition, individuals with CMT2 have loss of balance in the anteroposterior direction and with increasing severity of the disease these individuals need more vision for maintaining balance. Conclusion: Most studies of the systematic review evaluating balance and /or functionality also included in their assessments to measure muscle strength and sensitivity. Furthermore, studies have shown that the distal muscle weakness, especially ankle extensor plantar flexors and is associated with loss of balance and dynamic activities in the stop position, respectively. Clinical evaluations, conducted in CMT2 group and control group, showed that patients with Charcot-Marie-Tooth have less balance and loss of functional activity as compared to healthy subjects.
A doença de Charcot-Marie-Tooth (CMT) é a neuropatia periférica geneticamente herdada mais frequente em todo mundo. A maioria dos casos de CMT pode ser classificada em duas grandes categorias quanto à natureza da lesão primária do nervo: CMT tipo 1 e tipo 2. As principais manifestações clínicas são fraqueza muscular e diminuição da sensibilidade nas pernas e pés, alterações na marcha e equilíbrio. Os objetivos deste estudo foram realizar uma revisão sistemática sobre o equilíbrio e funcionalidade de indivíduos com a doença de Charcot-Marie-Tooth (CMT), assim como avaliar a força muscular, o equilíbrio e funcionalidade de indivíduos com a doença de Charcot-Marie-Tooth tipo 2 (CMT2). Métodos: Uma pesquisa abrangente na literatura foi realizada utilizando como base de dados a MEDLINE-PubMed, Web of Science, Scopus (1980- 2015). Além disso, foi realizado um estudo observacional e transversal, por meio de entrevista e avaliação clínica de indivíduos com a doença de CMT2 no município de Tobias Barreto. A amostra foi composta por um grupo com 15 pacientes com CMT2(GCMT2) e um grupo controle (GC), com indivíduos saudáveis pareados por idades e gêneros com o grupo CMT2. Os indivíduos com CMT foram classificados pela escala neuropática de Charcot-Marie-Tooth (Charcot-Marie-Totth Neuropathy Score - CMTNS) que avalia o grau de severidade da doença. A força muscular foi avaliada através de um dinamômetro manual. O equilíbrio foi mensurado através do baropodômetro footwork e da escala de equilíbrio de Berg. A avaliação funcional foi mensurada pelo teste Timed Up Go (TUG). Resultados: Na revisão sistemática foram selecionados 18 artigos. Os tipos de estudo que prevaleceram foram sobre avaliação do equilibrio e funcionalidade, tratamento de reabilitação e evolução natural da doença de CMT. A maioria dos estudos encontrou que a fraqueza muscular e alterações da sensibilidade estavam relacionadas à perda de equilíbrio e menor desempenho das atividades funcionais. No segundo artigo, houve diferença estatisticamente significativa entre o GCMT2 e GC para força muscular de todos os músculos avaliados (dorsiflexores: p= < 0.0001, flexores plantares: p= < 0.0001, inversores: p= < 0.0001, eversores: p= 0.0016), para os parâmetros VCoPAP e DCopAP da estabilometria para olhos abertos e fechados respectivamente (p= 0,0123; p= 0,0183, p= 0,0132, p=0,0129), para a escala de equilíbrio de Berg (p=0,0066) e para o teste TUG ( p = 0.0003). As correlações mais evidentes foram entre todas as variáveis analisadas e o CMTNS. Além disso, indivíduos com CMT2 apresentam perda de equilíbrio no sentido ântero-posterior e com o aumento da severidade da doença esses indivíduos necessitam mais da visão para manutenção do equilíbrio. Conclusão: A maioria dos estudos da revisão sistemática que avaliaram equilibrio e/ou funcionalidade também incluiram em suas avaliações a mensuração da força muscular e sensibilidade. Além disso, os estudos mostraram que a fraqueza muscular distal, especialmente de dorsiflexores e flexores plantares, está associada à perda de equilíbrio em atividades dinâmicas e a posição estática, respectivamente. As avaliações clínicas, realizadas no grupo CMT2 e grupo controle, revelaram que pacientes com Charcot-Marie-Tooth têm menor equilíbrio e prejuízo das atividades funcionais quando comparados aos indivíduos saudáveis.

Introdução: A síndrome SPOAN é uma doença neurodegenerativa, de transmissão genética autossômica recessiva, até o momento reconhecida apenas no Brasil, que caracteriza-se por: paraplegia espástica, de início nos primeiros anos de vida e caráter progressivo; atrofia óptica congênita; neuropatia periférica sensitivo-motora axonal, de início a partir da primeira década de vida; sobressaltos à estimulação sonora, disartria, deformidades de coluna e pés e sinais extra piramidais. A sua caracterização foi feita por nosso grupo, que avaliou clinicamente 71 indivíduos, originários do Rio Grande do Norte. Estudo de ligação mapeou o locus responsável pela síndrome SPOAN em uma região de 2 Mb no cromossomo 11q13. O gene responsável pela síndrome SPOAN permanece desconhecido. A síndrome SPOAN é considerada uma forma complicada de paraplegia espástica. A associação entre neuropatia e paraplegia espástica está relacionada à perda progressiva de axônios longos e tem sido relatada em algumas formas complicadas de neuropatias e paraplegias espásticas hereditárias. Casuística e métodos: Foi realizada a avaliação de 27 pacientes, 20 mulheres, com idade variando entre 4 e 58 anos. Todos os indivíduos compartilhavam o mesmo fenótipo (paraplegia espástica, atrofia de nervo óptico e neuropatia periférica) e tinham o mesmo haplótipo 11q13. Pacientes com história de diabetes mellitus ou alcoolismo foram excluídos do estudo. A avaliação neurológica incluiu a pesquisa dos escores modificados de sintomas e comprometimento neuropáticos. A força muscular foi testada e graduada conforme a escala MRC (Medical Research Council). Foi realizada a pesquisa da sensibilidade dolorosa, térmica, tátil, vibratória e artrestésica. O trofismo foi avaliado pela presença de deformidades na coluna e atrofia nos membros inferiores. Os reflexos profundos e o cutâneo plantar também foram analisados. Os estudos da condução nervosa foram realizados em um aparelho portátil Nicolet - Viking Quest, (Viasys, USA). Para os estudos de condução motora foram analisados os nervos axillar, mediano, ulnar, femoral, tibial e fibular direito. A condução sensitiva foi analisada nos nervos mediano, ulnar, radial, sural e fibular direito. O reflexo H e as ondas F foram avaliados com técnicas padrão. Alguns testes não puderam ser realizados devido à intensa atrofia e deformidades esqueléticas. O coeficiente de correlação de Pearson foi calculado entre a idade e os parâmetros, velocidade de condução, latência e amplitude. Valores de P < 0,05 foram considerados estatisticamente significantes. Resultados: Avaliação clínica: Todos os pacientes obtiveram escore de sinais neuropáticos graves e demonstraram déficit de força e atrofia distal. Deformidades dos pés estavam presentes em todos os pacientes e deformidades na coluna, em 58%. Os reflexos profundos dos membros superiores estavam exaltados em 92% dos casos e o reflexo patelar, em 63%. O reflexo Aquileu estava ausente em todos os pacientes. Todas as modalidades de sensibilidade foram afetadas, principalmente nos membros inferiores. Os dados do exame de sensibilidade na paciente de 4 anos foram desconsiderados. Estudo da condução nervosa sensitiva: Os SNAPs dos nervos mediano, sural e fibular estavam ausentes em todos os pacientes. SNAPs do nervo ulnar estavam ausentes em 96% da amostra e do nervo radial, em 80%. Estudo da condução nervosa motora: As latências motoras dos nervos axilar e femoral estavam normais em todos os pacientes. As amplitudes dos CMAPs estavam reduzidas em 15 e 52% da amostra nos nervos mediano e ulnar, respectivamente. Velocidades de condução estavam reduzidas em 50 e 41% desta casuística nos nervos mediano e ulnar, respectivamente. Velocidades de condução estavam acima de 80% do limite inferior da normalidade, em todos os nervos, exceto em 1 paciente que apresentou redução de 27% no nervo ulnar. Entretanto, este mesmo paciente apresentou amplitude menor que 2mV. Ondas F apresentavam aumento da latência, de acordo com a altura, em 100% dos casos. CMAPs estavam ausentes em 93 e 84% da amostra nos nervos fibular e tibial, respectivamente. Reflexo H estava ausente em 88% dos pacientes. Não houve correlação entre idade e a velocidade de condução, latência e amplitude dos nervos mediano e ulnar. Discussão: O estudo da condução nervosa neste grupo preencheu critérios para uma neuropatia primária axonal. Nenhum paciente apresentou bloqueio de condução ou dispersão temporal. As alterações encontradas na velocidade de condução provavelmente se devem à perda de fibras nervosas de condução rápida. Fenótipos SPOAN-like foram descritos em famílias com mutações nos genes C12orf65, TFG e OPA1. No entanto, não existem detalhes sobre a condução nervosa nestes pacientes. Neuropatia axonal de início tardio foi relacionada à SPG55 e DOA (dominant optic atrophy), enquanto neuropatia axonal e desmielinizante com leve comprometimento sensitivo foi descrita na família com mutação no gene TFG. Conclusão: Os pacientes com a síndrome SPOAN apresentam uma acentuada neuropatia axonal, sensitivo motora. As alterações encontradas na condução nervosa dos pacientes com síndrome SPOAN não são específicas, no entanto, resultados normais excluem esta condição em adultos. A paciente mais jovem desta casuística já apresentava alterações ao exame, o que pode sugerir um início precoce da neuropatia. Entretanto, não temos dados suficientes para afirmar que este seja um achado comum a todos os pacientes SPOAN
Introduction: SPOAN syndrome (Spastic Paraplegia, Optic Atrophy and Neuropathy) is a progressive neurodegenerative disorder of autosomal recessive inheritance described by our group in a large inbred family from Northeastern Brazil. The clinical picture is characterized by non-progressive congenital optic atrophy, progressive spastic paraplegia, axonal neuropathy, auditory startles, dysarthria, spinal and foot deformities and also extrapyramidal signs. Linkage studies mapped the responsible locus for the syndrome to a 2Mb region on chromosome 11q13. The gene responsible for SPOAN syndrome remains elusive. Materials and Methods: This is a cross sectional study which was conducted from 2009 to 2011. We evaluated 27 patients (20 females), with a0ges ranging from 4 to 58 years. All patients shared the same phenotype (spastic paraplegia, optic atrophy and peripheral neuropathy) and had the same 11q13 haplotype in homozygosis. Patients with history of diabetes mellitus or alcoholism were excluded from this study. All patients were evaluated by the same clinical researcher (SA). Neurological evaluation included determination of modified neuropathy symptoms (NSS) and neuropathy disability (NDS) scores. Motor strength was assessed using MRC scale. Sensibility assessment included small-fiber (pain and temperature) and large-fiber modalities (vibration-128Hz diapason, 10g monofilament and joint position sense). Spine deformities and atrophy in the lower limbs were observed. We also evaluated osteotendineous reflexes and cutaneous plantar reflexes. Nerve conduction studies were performed using a portable Nicolet - Viking Quest, (Viasys,USA). Motor conduction studies included axillary, median, ulnar, femoral, tibial and fibular nerves on the right side. Sensory nerve action potentials of median, ulnar, sural and superficial fibular nerves were recorded using a bar electrode of 3 cm and standard fixed distances. Tibial H-reflex was evaluated with standard technique. Minimal F wave latencies were obtained from ulnar and tibial nerves. A few tests could not be done in every patient due to severe deformities. We calculated Pearson\'s correlation coefficients between age and nerve conduction parameters, including velocities, latencies and amplitudes. P values <0.05 were considered statistically significant. Results: Clinical data: Neuropathic symptoms such as pain and paresthesias were rare. All patients had signs of severe neuropathy. All subjects demonstrated weakness and atrophy that were more significant distally than proximally. Foot deformities were present in all patients and spine deformities were seen in 58%. Upper limb deep tendon reflexes were exalted in 92% and patelar reflex in 63%. Ankle reflex was absent in all patients. In one patient, who was 4 years-old, sensory evaluation was inconsistent and the results were not considered. In all the other ones, sensory modalities were affected and occurred predominantly in the lower limbs. Electrodiagnostic data: Sensory nerve conduction: Median nerve SNAP was absent in all 27 patients. Ulnar nerve SNAPs were absent in 96%, whereas radial nerve SNPAs were absent in 80%. Superficial fibular and sural SNAPs were absent in all patients. Motor nerve conduction: The motor latencies of axillary and femoral nerves were normal in all patients. CMAP amplitudes were reduced in 15% of the median nerves and in 52% of the ulnar nerves. Conduction velocities (CV) were reduced in 50% of the median nerves and in 41% of the ulnar nerves. CV was above 80% of the lower normal limit for all nerves, except for one patient who showed a 27% reduction of ulnar CV, but had also a CMAP amplitude of less than 2 mV. F waves were prolonged according to the height in 100%. Only one patient who presented significant motor CV reduction of the ulnar nerve. CMAPs were absent in 93% of the fibular nerves and in 84% of the tibial nerves. A single fibular nerve showed more than 20% of CV reduction, but also had severely reduced CMAP amplitude. H reflex was absent in 88% of the patients. There was no correlation between age and neurophysiological parameters, such as median or ulnar CV, latencies or CMAP amplitudes. Discussion: Nerve conduction studies in this group fulfill criteria for primary axonal neuropathy. No patient showed conduction block or temporal dispersion. Abnormalities seen in CV and F waves are probably related to loss of fast conduction fiber nerves. We could not demonstrate correlation between age and nerve conduction parameters, including velocities, latencies and amplitudes. SPOAN-like phenotype has been found in families with mutations in C12orf65, TFG and OPA1 genes, however there is no detailed report on nerve conduction studies in these conditions. Axonal neuropathy is also described in SPG55 and DOA plus, but usually with a later onset than on SPOAN syndrome. Peripheral neuropathy is also described in the family with mutation in TFG gene, but this presents a different pattern characterized as a mixed axonal demyelinating neuropathy with mild sensory involvement. Although the nerve conduction abnormalities seen in SPOAN syndrome are not specific, normal results seem to rule out this condition, at least in adult patients. The younger patient in our series was 4-years-old, and her neurophysiological study was severely abnormal, suggesting an early-onset neuropathy. However, we do not have a comprehensive study of several young patients to support that this feature is

In the first part of the thesis Objectification of disorders of the fine motor skills of the upper extremities in the patients with hereditary neuropathies there are mentioned some brief informations about characteristics, classifications, clinical symptoms, deformities and testing of upper extremities, rehabilitation and treatment of CMT neuropathy. The practical part of this thesis is concerned with testing and evaluating of strength, fine motor skills and sensation of the upper extremities in the patients with CMT. For the measurement of the hand strenght the dynamometry and the functional muscle test are used. The Jebsen-Taylor test, the Nine-Hole Peg Test and the examination of static and dynamic handgrip rating are used. For the examination of the sensation the Nottingham Sensory Assessment is used. CMT neuropathy score and Overall Neuropathy Disability Scaleare are used for the classification of disability. The aim of this thesis is the comparison of the muscle strength and the function of the dominant and non-dominant hand. Partial aim of thesis is detection of the correlations between tests. According to the results CMT disease leads to the muscle strenght weakness and to worsening of the fine motor skills mainly of the dominant upper extremity. This may be the result of overwork weakness. For...

Aim: The aim of this thesis "Examination of vegetative system in hereditary neuropathy" is to consider the level of physical fitness, physical actvity level and quality of autonomic function in patients with hereditary neuropathy Charcot Marie Tooth and an assessment of interactions of these parameters, especially with regard to possible influence by the presence of autonomic neuropathy and with regard to neurological symptoms. Background: Although vegetative neuropathy was mentioned in the first publication about CMT, it is not widely discussed topic as part of it. Methods: Seventeen probands underwent spiroergometry, heart rate variability test, six minute walk test, rating by the CMT Neuropathy Score and Overall neuropathy disability scale and completing the IPAQ questionnaire. Results: We found symptoms of autonomic neuropathy in group of patients with CMT, especially high-frequency part of heart rate variability spectrum has a particularly significant decrease. Patients with autonomic neuropathy have shown a low fitness and functional capacity, tendency to obesity and hypertension. The observed correlation of autonomic neuropathy and neurological impairment was very weak. Conclusions: We find a neuropathy of the autonomic nervous system in patiens with hereditary motor and sensitive neuropathy...

In der Entwicklung des peripheren Nervensystems formen Schwannzellen eine Myelinscheide um Axone mit einem Durchmesser von mehr als 1 μm durch die Bildung multipler kompakter Membranschichten. Voraussetzung einer optimalen Nervenleitgeschwindigkeit ist dabei ein physiologisches Verhältnis der Dicke der Myelinscheide zu dem jeweiligen Axondurchmesser. Eine zentrale Rolle spielt dabei der axonale EGF-like growth factor NRG1 Typ III, der ErbB2/3- Rezeptoren der Schwannzelle bindet. Der PI3K-AKT-Signalweg ist ein bekannter intrazellulärer Effektor des ErbB2/3-Rezeptors und wurde bereits mit dem Prozess der Myelinisierung in Verbindung gebracht. Um die spezifische Funktion des PI3K-AKT-Signalwegs in Schwannzellen zu erforschen, generierten wir mit Hilfe des Cre/LoxP-Systems Mausmutanten, die eine zellspezifische Inaktivierung des Gens Phosphatase and Tensin Homolog (Pten) in myelinisierenden Gliazellen aufweisen (Pten-Mutanten). Der Verlust der Lipidphosphatase PTEN führte zu einer Anreicherung ihres Substrates, des second messenger Phosphatidyl-(3,4,5)-Trisphosphat (PIP3), und damit zu einer gesteigerten Aktivität des PI3K-AKT-Signalwegs in den Schwannzellen der Pten-Mutanten. Wir beobachteten in den Pten-Mutanten eine ektopische Myelinisierung von unmyelinisierten C- Faser-Axonen sowie eine Hypermyelinisierung von Axonen bis 2 μm Durchmesser. Bei Axonen über 2 μm Durchmesser kam es zu Myelinausfaltungen und fokalen Hypermyelinisierungen (Tomacula) anliegend an Regionen des unkompakten Myelins (Paranodien und Schmidt- Lantermann-Inzisuren). Weiterhin bildeten die mutanten Remak-Schwannzellen unkompakte Membranwicklungen um nicht-myelinisierte C-Faser-Axone und um Kollagenfaserbündel aus („Remak-Myelin“). Sowohl in den Regionen unkompakten Myelins als auch in Remak- Schwannzellen konnte eine erhöhte Aktivität des PI3K-AKT-Signalwegs nachgewiesen werden. Vermutlich setzt die Anreicherung von PIP3 mit Überaktivierung des PI3K-AKT-Signalwegs in den mutanten Gliazellen einen zellautonomen Prozess der Umwicklung von Axonen in Gang. Die zusätzliche Bildung von „Remak-Myelin“ um Kollagenfasern, die keine Membranoberfläche besitzen, weist darauf hin, dass dieser Prozess nicht von einer bidirektionalen axo-glialen Kommunikation abzuhängen scheint. Die beobachteten Tomacula und Myelinausfaltungen zeigten Ähnlichkeiten mit Mausmodellen für hereditäre Neuropathien des Menschen, wie HNPP und CMT4B. Wir vermuten, dass PTEN im unkompakten Myelin unkontrolliertes Membranwachstum verhindert und dass eine gestörte Balance von Phosphoinositiden einen Pathomechanismus von tomaculösen Neuropathien darstellt. Somit identifizieren wir den PI3K-AKT-Signalweg als ein mögliches Ziel zukünftiger Therapiekonzepte für hereditäre Neuropathien des Menschen.